Melanoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a muscle and skin condition called dermatomyositis and have tested positive for a specific antibody called anti-MDA5.
- People with anti-MDA5-positive dermatomyositis who also have a rapidly progressing form of lung scarring/inflammation (confirm with trial site for exact diagnostic details).
- People who have already had a procedure called bronchoalveolar lavage, where fluid is washed into the lungs and collected for testing.
- People aged 18 years or older.
- People who have signed a form giving their informed consent to take part.
Who may not be able to join:
- People who have other connective tissue diseases in addition to dermatomyositis.
- People whose lung condition is caused by an infection, a tumour, medications, chemical or biological factors, or other similar causes.
- People who are pregnant or currently breastfeeding.
- People who are already taking part in another clinical trial.
- People who do not agree to be included in this study.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 13716376758
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The relationship between the microbial community and the presence or absence of interstitial lung disease
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.